5.2% of the global population carry hemoglobin abnormalities, resulting in 300,000 to 400,000 children born with severe hemoglobinopathies annually.
Madrigal to grapple with lack of awareness about NASH ahead of potential FDA approval
Madrigal Pharmaceuticals may be first in line to bring a NASH drug to market, but the company is also tasked with teaching Americans and their
March 13, 2024